Crinetics Pharmaceuticals Inc [CRNX] stock prices are down -5.47% to $43.51 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CRNX shares have gain 12.52% over the last week, with a monthly amount glided 16.93%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 28, February 2024, Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update. In a post published today on Yahoo Finance, Phase 3 PATHFNDR-2 Study Topline Results Expected in March 2024; Pending Results, NDA Submission in Acromegaly Anticipated 2H 2024.
From an analyst’s perspective:
Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] stock has seen the most recent analyst activity on January 16, 2024, when Morgan Stanley initiated its Overweight rating and assigned the stock a price target of $50. Previously, Jefferies started tracking the stock with Hold rating on December 21, 2023, and set its price target to $35. Oppenheimer initiated its recommendation with a Outperform and recommended $40 as its price target on August 31, 2023. Piper Sandler started tracking with a Overweight rating for this stock on April 24, 2023, and assigned it a price target of $56. In a note dated March 30, 2023, Robert W. Baird initiated an Outperform rating and provided a target price of $48 on this stock.
The stock price of Crinetics Pharmaceuticals Inc [CRNX] has been fluctuating between $15.23 and $47.48 over the past year. Currently, Wall Street analysts expect the stock to reach $39.5 within the next 12 months. Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] shares were valued at $43.51 at the most recent close of the market. An investor can expect a potential drop of -9.22% based on the average CRNX price forecast.
Analyzing the CRNX fundamentals
The Crinetics Pharmaceuticals Inc [NASDAQ:CRNX] reported sales of 0.00M for trailing twelve months, representing a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -43.94%, Pretax Profit Margin comes in at -42.23%, and Net Profit Margin reading is -41.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is 0.62 and Total Capital is -0.35. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 41.77 points at the first support level, and at 40.02 for the second support level. However, for the 1st resistance point, the stock is sitting at 46.42, and for the 2nd resistance point, it is at 49.32.
Crinetics Pharmaceuticals Inc [CRNX] reported earnings per share of -$0.9 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.86/share, meaning a difference of -$0.04 and a surprise factor of -4.70%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.01 per share as compared to estimates of -$0.86 per share, a difference of -$0.15 representing a surprise of -17.40%.
Ratios To Look Out For
It’s worth pointing out that Crinetics Pharmaceuticals Inc [NASDAQ:CRNX]’s Current Ratio is 13.07. Further, the Quick Ratio stands at 13.07, while the Cash Ratio is 3.53.
Transactions by insiders
Insider trading, which has resulted in 0 insider purchases of 0 shares and 1 insider sales of 3,000 shares in the past three months, is now the topic of our analysis. Recent insider trading involved Betz Stephen F., Chief Scientific Officer, that happened on Jan 25 when 3000.0 shares were sold. Chief Scientific Officer, Betz Stephen F. completed a deal on Jan 10 to sell 3000.0 shares. Meanwhile, Chief Med and Dev Officer Pizzuti Dana sold 14375.0 shares on Jan 03.
